Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: US FDA Approves Novel Tetracyclines Nuzyra And Seysara; Hemlibra Indication Expands

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.
Advertisement

Related Content

Roche's Hemlibra Wins Expanded FDA Approval, Opening The Door To Broad Hemophilia A Opportunity
Pfizer Launches Nivestym At An Aggressive Discount To Other Filgrastim Products
Keeping Track: Busy August Ends With Approval For Doravirine, CRLs For Dasotraline And Waylivra
Paratek's Omadacycline Get US Panel OK, But CABP Mortality Remains Concern
Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar
Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review
Keeping Track: A Fresh Wave Of Approvals
Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris
Taiwan's ScinoPharm forges link for biosimilars production with US firm

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel